Overview

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of JNJ-55920839 following single ascending intravenous (IV) dose administration in healthy participants and a single subcutaneous dose in healthy participants and multiple IV dose administrations in participants with mild to moderate Systemic Lupus Erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC